Compare
Lexicon Pharmaceuticals, Inc. vs Gossamer Bio, Inc. vs Ocular Therapeutix, Inc vs Q32 Bio Inc.
| Latest fiscal year | Lexicon Pharmaceuticals, Inc. LXRX | Gossamer Bio, Inc. GOSS | Ocular Therapeutix, Inc OCUL | Q32 Bio Inc. QTTB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $49.80M | $48.47M | $51.95M | $53.74M |
| Revenue growth (YoY) | +60.2% | -57.7% | -18.5% | n/a |
| Gross margin | n/a | n/a | 87.3% (computed) | n/a |
| Operating margin | -98.2% | -352.2% | -519.8% | 31.5% |
| Net margin | -101.1% | -351.5% | -511.9% | 55.5% |
| Net income | -$50.34M | -$170.37M | -$265.94M | $29.82M |
| EPS (Diluted) | -$0.14 | -$0.75 | -$1.42 | $2.42 |
| Operating cash flow | -$67.85M | -$171.27M | -$204.88M | -$33.54M |
| Free cash flow | -$67.85M | -$171.34M | -$216.89M | -$33.54M |
| Cash & equivalents | $34.33M | $37.73M | $737.06M | $48.30M |
| Total assets | $184.99M | $172.25M | $808.06M | $61.78M |
| Total liabilities | $77.45M | $295.01M | $153.75M | $19.76M |
| Shareholders' equity | $107.54M | -$122.76M | $654.31M | $42.01M |
| Return on year-end equity | -46.8% | n/a | -40.6% | 71.0% |
| Shares outstanding | 365.85M | 233.68M | 215.93M | 12.86M |
Revenue, most recent five fiscal years
| Fiscal year | Lexicon Pharmaceuticals, Inc. | Gossamer Bio, Inc. | Ocular Therapeutix, Inc | Q32 Bio Inc. |
|---|---|---|---|---|
| Latest | $49.80M Ended 2025-12-31 | $48.47M Ended 2025-12-31 | $51.95M Ended 2025-12-31 | $53.74M Ended 2025-12-31 |
| 1 year earlier | $31.08M Ended 2024-12-31 | $114.70M Ended 2024-12-31 | $63.72M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $1.20M Ended 2023-12-31 | $0 Ended 2023-12-31 | $58.44M Ended 2023-12-31 | -$6.65M Ended 2023-12-31 |
| 3 years earlier | $139.0K Ended 2022-12-31 | $0 Ended 2022-12-31 | $51.49M Ended 2022-12-31 | n/a |
| 4 years earlier | $298.0K Ended 2021-12-31 | n/a | $43.52M Ended 2021-12-31 | n/a |